Questions discussed in this category
Is it necessary to do a taper afterward and what would be the recommended tapering schedule/duration?
Is it dependent on which DMT the patient is on?
Are there emerging biomarkers that help distinguish the phenotypes in the absence of evaluation over time?
E.g., JC virus antibody titer, absolute lymphocyte count, etc.
Are there contraindications to drugs like oxaliplatin or abraxane?
Does chronicity or severity of the patient's underlying symptoms play a role in yo...
1778721116186831868218681144801865417817121377851
Papers discussed in this category
Multiple sclerosis (Houndmills, Basingstoke, England), 2014-01
Ann. Neurol., 2018 Feb 15
Archives of ophthalmology (Chicago, Ill. : 1960), 2008 Jul
Neurology, 2014 May 28
Nature communications, 2020 Feb 10
Journal of clinical neurology (Seoul, Korea), 2024 Jan